In both of these studies, CagriSema was well-tolerated with an acceptable safety profile, with similar results reported in a phase 1b study in participants with overweight or obesity [7] and a phase 2 study in participants with type 2 diabetes [4]
With MASLD affecting millions globally, the potential to reduce both liver and metabolic complications through novel therapies is significant
While several of the interactions listed here are common to those seen between GLP-1 and its receptor, overall there appears to be many more specific polar interactions between Semaglutide and the GLP-1 receptor
But maintaining the body changes that happen while using GLP-1s often requires staying on the medication long-term potentially for life
My depression had been in remission before starting the medication, so this was a drastic shift
4,8 Treatment involves IV fluids and IV antibiotics (e.g., ceftazidime sodium plus metronidazole dosed according to renal function), bed rest, and eating nothing by mouth until symptoms subside